Jazz Pharmaceuticals
Search Results
23-04-06. AQ. GW PHARMACEUTICALS : SVB Leerink Downgrades GW Pharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $220 from $200. 21-02-04. MT. GW PHARMACEUTICALS : Morgan Stanley Downgrades GW Pharmaceuticals to Equal-Weight From Overweight, Adjusts Price Target to $220 From $193. 21-02-04.
- GW PHARMACEUTICALS PLC
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
People also ask
How much is gwph stock worth?
How much did GW Pharmaceuticals (gwph) earn?
What did GW Pharmaceuticals do in 2021?
Who is GW Pharmaceuticals plc?
Feb 3, 2021 · GW Pharma (GWPH) agreed to be acquired by Jazz Pharmaceuticals (JAZZ) for $7.2 billion in cash and stock. The deal values GWPH stock at a record high and gives Jazz a foothold in the cannabis-based drug market.
3 days ago · GW Pharmaceuticals plc (NASDAQ:GWPH) announced its earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.27. The biopharmaceutical company had revenue of $137.10 million for the quarter, compared to the consensus estimate of $97.66 million.
- SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ
- sschultz@gwpharm.com
- 441.2B
- 1.2K
May 5, 2021 · May 05, 2021. PDF Version. DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines. "We are excited to welcome our GW colleagues ...
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex Globe NewsWire - Tue Apr 20, 2021. – Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe –. GWPH : 218.96 (-0.15%)
Feb 16, 2021 · LONDON and CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription ...
